



OmvoH in Saudi Arabia

The SFDA named-patient coordination pathway — indicative 2026

IMMUNOLOGY · ULCERATIVE COLITIS, CROHN'S DISEASE

The clinical situation

OmvoH (mirikizumab-mrkz) is an anti-IL-23p19 monoclonal antibody FDA-approved for moderately-to-severely active ulcerative colitis and Crohn's disease. Manufactured by Eli Lilly. The regimen is IV induction (300 mg at weeks 0, 4, 8) followed by SC maintenance (200 mg every 4 weeks or 300 mg every 8 weeks depending on indication). Pre-treatment workup covers TB screening, hepatitis B/C, vaccination status, and LFTs given the hepatic monitoring requirement.

The pathway, 5 steps

- 1 Consultation & clinical rationale.** Your gastroenterologist documents UC or Crohn's activity, prior biologics, and OmvoH rationale.
- 2 Baseline screening.** TB, hepatitis B/C, vaccinations, LFTs, and infection review completed per FDA labelling.
- 3 SFDA named-patient application.** Physician or hospital pharmacy files clinical rationale, patient reference, induction-maintenance calendar, and chain-of-custody commitment.
- 4 US-side sourcing & cold-chain logistics.** Reserve Meds coordinates product through our US-licensed DSCSA-compliant specialty wholesale partner with validated 2–8°C shipment.
- 5 Arrival & first infusion.** Infusion facility administers IV induction; subsequent SC maintenance transitions to home or clinic per protocol.

Indicative economics

Reference US cash-pay range: USD 18,000–22,000 per OmvoH maintenance dose (drug-only reference; Reserve Meds provides a transparent delivered quote at intake).

Indicative first-dose timing

7–14 days from a complete SFDA application to first dispensation, once cohort intake opens. Indicative — not guaranteed.

Reserve Meds's role

Sourcing. US-licensed specialty wholesale partner, DSCSA chain-of-custody from Eli Lilly authorised distribution.

Documentation. Physician kit tailored to SFDA review, with IL-23p19 class safety annex. **Logistics.** Validated cold-chain internationally tracked shipment. **Concierge case lead.** Named point of contact for family and physician through induction and maintenance. **We are a coordinator** — not the prescriber, not the dispensing pharmacy. All clinical decisions remain with your treating physician.

COMPOSITE EXAMPLE · PRE-LAUNCH WAITLIST

Join the Omvoh × Saudi Arabia first-cohort waitlist. *Our concierge reaches out as we open intake.*

reservemed.com/access-guides/omvoh-saudi-arabia.html



SCAN TO JOIN

Reserve Meds · US-based concierge for cross-border specialty medicine. We are a coordinator; we are not the prescriber and not the dispensing pharmacy. All clinical decisions remain with the treating physician. Not medical advice.

Reserve Meds is in pre-launch. Service availability is limited to our first cohort; all timelines published are indicative, not guarantees. Composite case examples only.

reservemed.com · hello@reservemed.com · WhatsApp concierge: +1 516 528 3120 · Reviewed 2026-04-23 by Reserve Meds clinical & regulatory team